NHI payment possibility for anti-obesity medications attracts keen interests.

Published: 2007-08-10 06:59:00

Updated: 2007-08-10 06:59:00

On July 25 the Seoul District Administrative Court decided that the anti-obesity medication should be deemed as an eligible subject to include the NHI reimbursement scheme unless the treatment was purported for an aesthetic surgical operation such as an abdominal extra fat suction. Since then, th...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK